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~ O n o  Year Follow-up of the ESSENCE Trial 
(~noxepadn Vet=us Hq~r ln  In UnMabl~ Ang ina  and 
Non.Q.Wave Myoaaldial Infarction) 
tt~ ESSENCE Gm~lp: Altt~t~lly Ut'~Fve!~!!y ~ta l ,  Ptltt~l~tptl~, PA U~A 
~rg~t  ~"~i~ IRA}, my~"~lU~l inf~F~l~ IMll o{ ~=3th (~)) in p~tlents w~th 
~n,~t~lg~ tn~3 ~ ~ O wavq= r~rd~!  nf~f~ton in th# e,~dy (t4--30 
y~r  l~f~w~gg ~grv W w~ I~o~pe¢tlv~ly g~d~ken for ¢~¢h p,~tient enrotle_~ 
m tt'~. E~I~NCE s t~ry Th~ ~t~tus__ ¢l all p~tien~ w~5 to ~ L~term~ ~y 
e~¢h ~it~ ~ mlqnn~tioft i@!~~ lh¢ e~_¢u_neeu;e el e:tdpoJe~ IP-./dMt, D), 
~ne~O~lL~ty e¢ ~v~;~3n.~t ion  ~¢h j re~ ~nd r~-ho_~pit~!Lz~tions_ were 
¢~l¢~;b~J AS 6| A~J~I  1~)7, L~_~ h_~v¢ ~een collect_ ed on !4~ p~tients. At 
CJ~V 30, the rate el I~MI /O  w_~_ 23_,3% t~ h_~nn and !9.8% for errata. 
penn, a re~iat~ ffsk f edu~n iRRR) el 15%; the f~te A MLzD Was 7.7% for 
hepafln a~ 6~% for e no~,~p.3nn, a RRR el ~O%r Afi6r O~ yaa~ t~ ~le  
el FL~ML/i) was _266% l~ h~el~=nn and _2~.~ 8% lot enexa_pann (RRR 14%); 
th~ r~t@ Q| MtiO wa~, 8 .~ ['of hepafln and 7.2% fOl' enoz,~oann (RRR 19%)= 
morea.ling the ben~tit aclueved in ~ early p~e iS sust~ned over one year. 
All data _should be collected by Septem~Zzer 1997 Full results el the study wdl 
be pres.~.ted 
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~ Prognostic Value of ECG Changes Oudng Chest 
Pakl in Patients With Unstable Angina. Results of 
the Proyecto de Estudio del Pronostico de la Angina 
(PEPA) 
E. L0pez ~ Sa, J. Lepez-Senden. A. Bethencourl, X. Bosch. The PEPA 
~nvestigato~=: i-t.Gregorzo Mareftdn, Madrid. Spare 
Background: Rel:](danzati,J. ECG changes Outing an episode of pain =n 
patients with suspected unstable angina (UA) or non-Q myocard=al infarction 
(N-O MI) are considered as very specific for myocardial ischemla. However, 
its prognostic value was not prospectively studied in large senos of patients 
Methods: The prognos~c value of =schenuc ECG changes obtmned dunng 
the first obsen.,ed episode of pain as campa~ed to the ECG without pain was 
prospectively evaluated in 1899 consecutive patients considered to have UA 
or N-Q MI when first seen by a cardiologist at 18 centers in Spain. 
Results: Modality at 90 days follow-up was higher when ST segment 
depression -_'0.1 mV was obsonred dunng pare and lowest when both ECG 
(with and without pain) were normal. The figure shows the Kaplan-Meyer 
survival curves for the different groups 
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Conclusion: Downward shift of ST dunng pain is the variable related w;th 
highest mortality in patients ~th  suspected UA. 
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I -~-~ Prognost ic  o f  I schemia in S ign i f i cance  Refractory  
Unstable Angina Revisited 
P. Theroux, O. Bazzino, E. Barr, S.M. Snapinn. F.L Sax. Montreal Heart 
Institute. Montreal. Canada: Merck Research Laboratones. West Point. PA. 
USA 
Background: Refractory ischemia (RI) in acute ischemic syndromes is asso- 
ciated with a poor prognosis that usually mandates aggressive management. 
The purpose of this study was to reassess its prognostic significance in the 
setting of full antithrombotic therapy including aspirin. IV heparin, and a GP 
IIb/tlla platelet inhibitor. 
Methods: The PRISM-PLUS trial randomized 1,570 patients with unstable 
angina/non-Q-wave MI to hepann alone (H) or to tirofiban + heparin /T/H). 
Study drug was administered for 48-108 hours. Angiography ± PTCA was 
perforated if necessary between hours 48 and 96. Aspirin was given to 98% 
of patients, nitrates to 94%. beta blockers to 79%, and calcium antagonists 
to 46%, e l  trte total ~tud"/ pO~'Jl~ti00 ~ ~t~ents (~ 4%.) L~Ve~Cp~ RI ~n 
the ti~t 48 hour~ Of therapy (5 9% v~ 48% an ~tient~ re.c;¢w~n O H 0r T/H, 
f¢~l[~Chv¢ty) 
/~#~ult~ Pat!e~tts w+lh RI w!th*n 1h¢ tif~t 4~ t'~o~r~ 1~1 ~ ru~P.~ ~r'~t~crt¢~ o  
~u~sequent ~th  o~ MI at 30 d~y~ v~ E-~ti~nt~ witr~ut RI ( 155% v~= ~5% 
,~v, r~tio [RR] = t 95, 95% confidence lnt~,~ls [CIJ ~ 1. f 0-~3~44, ~= 0 0,?-~'} 
The_ m¢_tden¢~ of (~taath o~ MI in RI ~tl(~ntc= f~c~vin 9 Id Of T~H w~ ~55% 
135%. Reva_sau!~ri~tio~ w~s ~orm _~ !F= 1~9_ 4% of H [~t=~nt _s with RI 
in 6_7,6% of TIH IP~t=@nt~ with R! IRR _= 0,76, CI = 0,59-0.97, ~ = 0,0141 Tr~ 
Igr _~gc~!Qr~ w~ I~f tor~ g f~nW iO 4.4% Of l~t¢#fit§ in ~ 14 gr¢~ ~n~l ~n 
3,4% 0'J the= pat~nt=~ in the_ TtH g~ol~p (RR -= 0,77, ¢1 ~ 047=t ~0) 
Conc_i~t,~c~n: Retr~¢to~ i~¢homi~ in uns_t_a_~¢ ~gtn~non--Q-w~ve myo~af. 
O=~t infar~LO~ I~i ~55oelate¢l with ~.wr¢ pr0~l~_~i_s L~=~51~te tuft ~ tf~t, 
me.fit Inhibition el t!"~ (~P !!i~ii!~ r~:epto~' w~th tir0fib~T~n plu~s hel~fin zmpf(~v~ 
Die,]nests_ in thes~e p~t~ents 
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~ Hlmel=!n Recluaes I~ath and Myoaerd~l 
(Re)infarction et @Months: Follow~-up Results of the 
GUSTO I!b Trial 
C.0. Granger, F Van de Wed, PW Armstror~g, J Simes, H. White, 
C M MacAulay. R M. Califf E J Topoi For the GUSTO lid Inveshgators, 
Ouka Unwers~ty Medical CenleF, Durham, NC; Cleveland Chn~c Foundation 
Clove~and. OH, USA 
Background." Longer term follow.up o! tnals of new ant(thrombotic therapy 
for coronary artep/disease is *mpodant because eady treatment e f fe~ may 
not porsi~ or can be accentuated. 
Methods: In the GUSTO lib thai, 12,t42 patients presenting within 12 
hours of symptom onset of acute coronary syndromes were randomized to a 
three day infusion of intravenous hirudin or nepann. Follow-up at 6 months 
and 1 year is 98.0% and 93% ;omplate, respectively 
ResultS: 
ntrudin hepann p-value 
30 day (re)Mi b 4'% 63% 0 04 
6 rn~n~ (relM] 7 1% 82% 0 035 
30 day death or (relMI 89°0 9 8% 0 058 
6 month death or trelMI 12 3% 136% 0 039 
I year rr.Qna~ry 9.0% 92°° 068 
(" Pearsons ohm-square t st) 
Conclusion: Hip~din is effective at reducing death or MI at 6 months, There 
=s no suggestion of either narrowing or accentuation of the early benefit el 
hlrudln, w~th the absolute and proportional reduction maintained from 30 days 
to 6 months. 
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F8--2~ Failure to Achieve Optimal Ant(coagulation With 
Commonly Used Heparln Regimens; A Review of 
GUSTO il 
A. Wali, J.S. Hochman, S. Berkowitz. KA. Clark, S. Mainotra, R.M. Califf, 
C. Granger. St. Luke's-Roosevelt Hospital Center, Columbia University. New 
York: Duke University Medrcat Center, Du~am. NC, USA 
GUSTO I da~ on thrombolytic treated pls on IV hepann demonstrated aclear 
association of higher aPTT's (75 sac) and death, bleeding and re-Ml. AHCPR 
guidelines recommend a 70 U/kg IV Bolus (B) and a 15 U/kg/hr infusion. We 
evaluated aPTT's of 5571 pts in GUSTO lib who received 5000U of hepann 
IVB and 1000 U/hr with (n = 1543) or without (n = 4028) thrembolytic5 
and divided them into sub-therapeutic (aP1-F <50), therapeutic (50-75 sec) 
and supra-therapeutic (775 sec) groups. We examined aPTTs of pts who 
we,ghed 67-72 kg (approx 70 U/kg IVB and 15 U/kg/hr) and .67 kgs (LBW) 
Results: 6 hr aPl-r's of pts 67-72 kg were therapeutic in only 21% with 
71% supra-therapeutic, s~milady LBW pts were overwhelmingly suprathera- 
peutic at 84% with 11% therapeutic. When 67-72 kg pts were divided rote 
thrembelytic and non-thrembolytic groups, 80% and 68% were supra-thera- 
peutic with 15% and 23% therapeutic respecbvely. The median aPTT at 12 
hours was significantly higher in pts with 30 day death and re-MI 69 (52. 
95) vs 66 (52, 89), p = 0.029. This remained true in the non-thrombolyhc 
subgroup 69 (54. 93) vs 66 (52, 86), p = 0.023. Moderate/severe bleeding 
was associated with significantly aPTT's 68 (53, 95) vs 66 (52.89), p = 0.028. 
Conclusion: AHCPR hepann dosing guidelines, and fixed hepann dose 
(5000/1000) for LBW pts with acute coronary syndromes result in consis- 
tent eady over antieoagulation regardless of thrombolyt~c status and this is 
associated with increased risk of death, bleeding and re-Ml. 
